About Techsomed Medical Technologies

Techsomed Medical Technologies is an Israeli medical software company that leverages generative AI to enhance ablation therapy, a minimally invasive technique used for treating tumors, heart arrhythmias, and chronic pain. Their flagship product, the BioTraceIO360 software suite, focuses on liver tumor ablation procedures. The system utilizes standard medical imaging modalities like Ultrasound, CT, and MRI to provide physicians with real-time tissue damage prediction, advanced patient-specific treatment planning, and interactive ablation procedure analysis. This aims to improve treatment precision, safety, and outcomes while reducing costs.

In January 2024, Techsomed’s BioTrace solution achieved De Novo clearance from the FDA, making it the first ultrasound-based software for tissue response prediction in liver tumor ablation. The company further expanded its BioTraceIO360 platform in September 2025 by receiving FDA 510(k) clearance for kidney ablation, demonstrating a strategic move towards a unified multi-organ image-guided therapy platform. Techsomed has also announced a collaboration with Medtronic in October 2025, focusing on image-guided ablation therapy, combining Techsomed’s software with Medtronic’s Emprint microwave ablation system to support interventional radiologists throughout the full cycle of ablation management.

Focus Areas

AI-powered image-guided ablation therapy real-time tissue response monitoring oncology (liver kidney tumors) cardiology (heart arrhythmia) pain management

Business Intelligence

TechnologyBioTrace™ platform (BioTraceIO, BioTraceIO360, VisAble.IO), AI-powered, hardware-agnostic, integrates with standard commercial ultrasound devices, unifies CT, MRI, and ultrasound data, generative AI

What Physicians Need to Know

AI-Powered Image-Guided Ablation Therapy
Techsomed specializes in AI-powered image-guided ablation therapy, utilizing its BioTrace™ platform to provide real-time visualization and analysis of tissue viability during thermal ablation procedures. This technology aims to improve treatment precision, safety, and outcomes.
Real-Time Tissue Response Monitoring
A key differentiator is Techsomed's ability to offer real-time tissue response prediction. Their BioTraceIO software analyzes ultrasound images to visually simulate the post-24-hour thermal effect during the procedure, eliminating guesswork and enhancing control for physicians.
Oncology (Liver & Kidney Tumors)
The BioTrace™ platform is used for tumor destruction in organs such as the liver and kidney. Techsomed's BioTraceIO has received FDA clearance for liver tumor ablation and expanded indications to include percutaneous ablation of soft tissue in the kidney.
Cardiology (Heart Arrhythmia)
Techsomed's technology also extends to cardiology for treating heart arrhythmia, providing real-time image analysis during thermal ablation procedures.
Pain Management
The BioTrace™ platform is applicable in pain management, specifically for procedures like radiofrequency neurotomy.
Key Differentiators
Techsomed's key differentiators include its AI-powered, hardware-agnostic BioTraceIO360™ platform that unifies planning, execution, and monitoring of image-guided ablation therapy. It integrates with standard commercial ultrasound imaging systems, unlike some competitors requiring specialized hardware. The system provides real-time visualization, predictive margin control, and dynamic treatment planning.
Technology Stack
The core of Techsomed's technology stack is the BioTrace™ platform, which leverages advanced proprietary AI and image analysis. It integrates and unifies CT, MRI, and ultrasound data into an intelligent clinical workflow powered by generative AI.
Physician Tip

Techsomed's BioTraceIO360™ platform offers physicians enhanced precision, safety, and consistent outcomes in minimally invasive ablation treatments. The real-time predictive modeling and visualization, coupled with dynamic treatment planning, allow for greater control during procedures and help in maintaining local control of tumor margins, potentially reducing the need for repeat interventions. The hardware-agnostic nature of the software means it can integrate with existing commercial ultrasound, CT, and MRI systems, facilitating adoption and reducing the need for specialized imaging hardware. This technology transforms thermal ablation therapies from guesswork into precise, feedback-dependent treatments. The expanded FDA clearance for kidney ablation, in addition to liver applications, broadens its utility for interventional radiologists.

Techsomed's BioTraceIO360™ software is designed to integrate with standard commercial ultrasound imaging systems, as well as CT and MRI data from PACS systems. Notably, Techsomed has a pilot collaboration with Medtronic, combining its BioTraceIO360™ software with the Medtronic Emprint™ microwave ablation system to offer a complete solution for image-guided ablation therapy.

Products by Techsomed Medical Technologies

No products listed for this company yet. Know of one? Suggest it →

Reviews & Opinions

No web reviews on file yet for Techsomed Medical Technologies. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about Techsomed Medical Technologies.

Loading videos...

Videos load interactively. If none appear, search YouTube for Techsomed Medical Technologies →

View all on YouTube

Press & Coverage

BioSpace
Techsomed's BioTrace Solution Achieves De Novo Clearance from FDA as the First Ultrasound-Based Software for Tissue Response Prediction in Liver Tumor Ablation
Techsomed Medical Technologies LTD announced that its BioTraceIO, an ultrasound-based liver ablation software for tissue response prediction, has received De Novo clearance from the FDA. This marks a significant step towards commercialization in the USA, offering physicians enhanced precision in ablation therapy.
2024-01
Healthcare IT News
FDA grants real-time liver ablation AI clearance
The U.S. Food and Drug Administration granted De Novo clearance to Techsomed's BioTraceIO, an AI-powered ablation treatment platform that analyzes ultrasound images to track tissue response during liver ablation treatment. This clearance is considered a game-changer for image-guided ablation therapy.
2024-01
American Technion Society
Liver Tumor Treatment Gets a High-Tech Upgrade
Techsomed Medical Technologies, an Israeli company, received FDA De Novo clearance for its BioTraceIO software, which predicts tissue response to ablation therapy and provides real-time visuals during liver tumor removal. The company's founder and CEO, Yossi Abu, and Chief Strategy Officer Eran Naveh are Technion alumni.
2024-01
PLOS ONE
Retrospective evaluation of a novel ultrasound-based imaging analysis software for predicting radiofrequency ablation areas
This peer-reviewed article evaluates BioTrace, a novel software from Techsomed Medical Technologies, designed for real-time monitoring of thermal ablation tissue damage during image-guided radiofrequency ablation for hepatocellular carcinoma. The study found that BioTrace effectively generates an ablation damage prediction map, accurately predicting the ablation zone.
2025-01
Synapse
Techsomed Announces FDA Clearance for Ablation Treatment Planning and Confirmation Software
Techsomed announced FDA clearance for its ablation treatment planning and confirmation software. This software assists physicians in planning ablation procedures, including identifying targets and virtual needle placement, and confirming ablation zones.
2023-09
PR Newswire
Techsomed and Medtronic to Collaborate on Image Guided Ablation Therapy
Techsomed and Medtronic are collaborating on image-guided ablation therapy. This partnership aims to further develop and commercialize Techsomed's BioTraceu2122 system, which provides real-time predictive imaging for thermal ablation procedures.
2025-10
CTech
Cancer Treatment Monitoring Startup Techsomed Raises $2.6 Million
Medtech startup Techsomed Medical Technologies Ltd. raised $2.6 million in a funding round led by Johnson & Johnson Innovationu2013JJDC Inc. The funding will be used to obtain regulatory approval in the U.S., European Union, and Japan for its image analysis system that tracks tissue response to thermal ablation.
2019-05
PR Newswire
Techsomed Secures $2.6M for Groundbreaking Real-time Predictive Imaging System for Thermal Ablation
Techsomed secured $2.6 million in a financing round led by Johnson & Johnson Innovation u2013 JJDC, Inc., to further develop its BioTraceu2122 system. This system is the world's first image analysis system for predicting post-treatment ablation morphology in real-time, aiming for FDA, PMDA, and CE regulatory approval.
2019-05

Frequently Asked Questions

Techsomed Medical Technologies specializes in AI-powered image-guided ablation therapies, primarily focusing on oncology for liver and kidney tumors, and cardiology for heart arrhythmias. Their technology aims to enhance precision and efficacy in these critical areas, offering advanced solutions for interventional procedures.
Techsomed's real-time tissue response monitoring system utilizes advanced AI algorithms to provide immediate feedback on tissue changes during ablation. This allows physicians to dynamically adjust treatment parameters, optimizing therapeutic effect while minimizing damage to healthy tissue, thereby improving patient outcomes and safety.
Techsomed offers innovative platforms designed for image-guided ablation, with specific applications in oncology for treating liver and kidney tumors, and in cardiology for managing heart arrhythmias. While the primary focus appears to be on these areas, the precision and real-time monitoring capabilities could have future implications for pain management interventions requiring targeted ablation.
Techsomed Medical Technologies is committed to regulatory compliance, though specific certifications like FDA or CE Mark would need to be confirmed directly with the company. Regarding pricing, it typically involves a capital expenditure for the system, potentially with per-procedure or subscription-based fees for software and support, reflecting the advanced nature of their AI-powered solutions.
Techsomed provides comprehensive support including initial installation and training for medical staff to ensure proficiency with their ablation systems. Ongoing technical support, maintenance, and software updates are typically part of their service agreement, aiming to maximize system uptime and operational efficiency for healthcare providers.
Techsomed Medical Technologies is actively pursuing partnerships with leading medical institutions and research centers to further validate and advance their AI-powered ablation technologies. As an innovative company in a rapidly evolving field, their stability is supported by strong investor interest and the growing demand for precision medicine solutions in oncology and cardiology.

Related Companies

OrthoAI is a healthcare AI company that has two distinct entities. One OrthoAI, based in India, is an AI-powered surgical companion designed for orthopedic surgeons, providing evidence-based insights and decision support. It functions as a generative AI, similar to ChatGPT, specifically tailored for orthopedics, and is accessible 24/7. This platform integrates a curated database developed […]

NuvoAir is a digital health company that provides a value-based specialty care platform focused on proactive, continuous virtual care for individuals with heart and lung conditions. The company aims to transform the diagnosis and management of chronic cardiopulmonary conditions by integrating advanced monitoring technology, data analytics, and evidence-based interventions delivered by a multidisciplinary team. NuvoAir’s […]

Infinite Biomedical Technologies, LLC (IBT) is a medical device company established in 1997 with roots at Johns Hopkins University. The company is dedicated to developing innovative solutions for individuals with upper limb loss and differences, aiming to transform laboratory research into practical medical devices. IBT focuses on advanced prosthetic control systems and related technologies to […]

The search results indicate that “Strain AI” is not a single, unified company serving physicians and healthcare providers in the traditional medical sense. Instead, the term “Strain AI” appears to be a general descriptor used by several distinct companies operating primarily in the cannabis industry, leveraging AI to recommend cannabis strains based on user preferences, […]

Samsung is a global technology leader that has significantly expanded its presence in the healthcare sector, leveraging its expertise in AI, imaging, and connected devices. The company aims to improve patient care and outcomes by providing advanced diagnostic solutions, personalized health insights, and integrated digital health platforms. Samsung’s healthcare initiatives focus on bridging the gap […]

Philips (Cardiologs) is a healthcare AI company that specializes in transforming cardiac diagnostics through medical-grade artificial intelligence and cloud technology. Their core offering is the Cardiologs Holter platform, which utilizes deep neural networks to analyze continuous ambulatory ECGs. This platform is designed to streamline ECG analysis, reduce reporting errors, and accelerate diagnostic reporting, ultimately empowering […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.